Este es el título. No debe exceder de 50 palabras. Calibri Cuerpo.

Tamaño de
fuente máxima 50

Calibri tamaño máximo 33. Negrita. Apellidos y Nombres autor 1, Apellidos y Nombre autor 2 2,3, Azamor T1 , Nodarse Cuni H4, Dornelles Picon P5,
de Souza Matos D1, Ozório Moraes M2

1
Estudiante Carrera de Medicina, Universidad Franz Tamayo (UNIFRANZ), Cochabamba, Bolivia.
2
Docente Carrera de Bioquímica y Farmacia, Universidad Franz Tamayo (UNIFRANZ), La Paz, Bolivia.
3
Sociedad Científica de Estudiantes de la Carrera de Medicina, Universidad Franz Tamayo (UNIFRANZ), Santa Cruz, Bolivia.
4
Docente Carrera Enfermería, Universidad Franz Tamayo (UNIFRANZ), El Alto, Bolivia.
5
Medico Internista, Hospital San Juan de Pedro

INTRODUCCIÓN (Calibri Tamaño de fuente máxima 35. Mayúsculas, M ostof the genes
, had elevated expression levels before treatm ent,except
negrita) for IFNA1, IFNAR and IFHI. Overall, they had a decline in week 1 and a
significant higher expression levels in later time points. In week 1 during
treatment. CC homozygote patients for rs12979860 had lower gene
Texto Calibri. Tamaño de Fuente máxima 32. Negrita expression levels, compared to patients that carried the risk allele T, this was
D engue is -an arthropod-borne viral disease w ith clinical m anifestations observed for IFI6, IFI16, IRF9 and RIGI. In contrast, relative mRNA
varying from mild fever to severe and potentially lethal forms . An expression for IFH1 and RNASEL were subtle higher in patients with CC
increasing num ber of genetic studies have outlined the association genotype.
between host variations and dengue severity. Genes associated to viral
recognition and entry, as w ell as those encoding m ediators of the
immune response against infection are strong candidates for association
studies.
CC
CT
MÉTODOS (Calibri Tamaño de fuente máxima 35. Mayúsculas, 10
negrita) *** TT
*
Relative Expression
IFNL3 mRNA 3.2
Texto Calibri. Tamaño de Fuente máxima 32. Negrita
W e evaluated the expression ofgenes ofthe type IIFN signaling pathw ay in
24 CH C patients treated w ith pegylated interferon plus ribavirin and 1
further stratified according to rs12979860 polymorphism. Samples were
evaluated at different time points (time 0, week 1 and week 12 during 0.3
treatm ent and w eek 3 after treatm ent). A llelic discrim ination w as
performed using Taqman Genotyping SNP assay (AHBKCW 9,
Therm oFisher). Expres30 sion levels for 30 Type I IFN genes w as 0.1
evaluated using Biomark HD System (Fluidigm). Kruskal-Wallis and Dunn ´s 0 1ª 12ª
post tests were used for comparisons.

RESULTADOS (Calibri Tamaño de fuente máxima 35. Mayúsculas, negrita)

CC
10 CT
*** TT CONCLUSIÓN (Calibri Tamaño de fuente máxima 35. Mayúsculas,
Relative Expression

3.2 negrita)
IFNL4 mRNA

1 Texto Calibri. Tamaño de Fuente máxima 32. Sin negrita

Gene expression levels in Type I IFN signature genes was different according to time
points evaluated and also when patients were stratified according to rs12989860
0.3 polymorphism

Bibliografía (Calibri Tamaño de fuente máxima 35. Mayúsculas,

0.1 negrita)
0 1ª 12ª Formato Vancouver de citación. Alineación a la izquierda
Calibri, Tamaño de Fuente máxima 28. Sin negrita.